Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of the Revised Aldosterone-Renin Ratio (ARR) Cutoff in the 2025 Primary Aldosteronism Guideline in Real-World Practice: A Prospective Study

NCT07621458 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT07621458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07621458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of the Revised Aldosterone-Renin Ratio (ARR) Cutoff in the 2025 Primary Aldosteronism Guideline in Real-World Practice: A Prospective Study
Lead sponsor
Seoul National University Hospital
Phase
Observational
Overall status
Recruiting
Start date
April 1, 2026
Completion date
December 31, 2027
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary aldosteronism